Dualyx, a Zwijnaarde, Belgium-based biotechnology company which specializes in advancing immune modulators, raised €40M in Series A funding.
The round was led by Andera, Fountain Healthcare Partners and Forbion with participation from existing investors V-Bio Ventures, BGV, PMV, VIB, HTGF, and GFF. Aneta Sottil, Director at Andera Partners will join Dualyx Board as non-executive director.
The company intends to use the funds to progress its lead autoimmune program DT-001, as well as its pipeline of Treg-targeting candidates.
Founded in 2020 by Luc van Rompaey in a collaborative model with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven and led by CEO Wouter Verhoeven, Dualyx is a biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. It has developed a pipeline of immune modulating programs including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2) which is currently in IND-enabling studies. TNFR2 is a master control switch in for immunosuppression for Treg therapies.
FinSMEs
15/05/2023